ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SCIEX and Bioinformatics Solutions Inc. Further Collaboration for Proteomic Advancement

SCIEX, a global leader in life science analytical technologies, and Bioinformatics Solutions Inc. (BSI), provider of next-generation, deep learning proteomics and AI-driven biotechnology solutions, advance their collaboration with the co-development of PEAKS 12.5. This new software launch is fully compatible with the ZenoTOF 7600+ system, offering exclusive commercial support of ZT Scan DIA for proteomics applications.

In this latest software platform release, the unique de novo assisted pipeline together with deep learning algorithms exploit the data acquired from the scanning Q1 quadrupole dimension by ZT Scan DIA. The software does this by utilizing a new scoring algorithm integrating DDA and DIA data analysis approaches to reflect the increase in sensitivity and accuracy of identification and quantitation results achieved by the ZenoTOF 7600+ system. The Q1 dimension gives the data the DDA-like quality by associating precursor information to the MS/MS scans, thus improving accuracy and increasing identification and quantitation rates.

In addition, the software displays the Q1 profile of each identified peptide in an interactive GUI so that results can be easily interpreted and validated. Visualization of the Q1 profile demonstrates the added ability to deconvolve co-eluting fragment ion signals originating from native and modified peptides.

“Proteomic scientists need to know what the data looks like and why it’s happening, especially as results are brought into the medical field. PEAKS 12.5 is the only software tool to allow researchers to visualize the Q1 dimension from the ZenoTOF 7600+ system, meaning you can see the quality, the peak shape, the curvature. This can improve accuracy and scoring, and also help visually differentiate isomers,” said Baozhen Shan, Chief Executive Officer & Chief Scientific Officer at BSI.

“We are excited to build upon the collaboration with BSI that we set out on earlier this year. Together, SCIEX and BSI aim to help the proteomics community gain confidence in their data and translate their results into meaningful, actionable biology. Through our collaborative efforts of exploiting the multidimensional data from the ZenoTOF 7600+ system, we hope to see advancements to the role of proteomics research within precision medicine,” said Jose Castro-Perez, Vice President, Product Management.

To learn more about PEAKS Studio, see https://www.bioinfor.com/peaks-studio/.

This announcement marks the expansion of the relationship between SCIEX and BSI, as SCIEX becomes an official commercial reseller of the PEAKS Studio platform.

About SCIEX

SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

SCIEX is proud to be part of Danaher. ​

Danaher’s science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2024 DH Tech. Dev. Pte. Ltd. MKT-33273-A.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.